Form D · Pharmaceuticals

CERO THERAPEUTICS HOLDINGS, INC.

South San Francisco, CA · CIK 0001870404

Offering snapshot reported May 6, 2025 · SEC filing

Reported sold: $5M
Investors reported: 5
Minimum accepted: $0
First sale: Apr 22, 2025

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
May 6, 2025	Initial	$5,000,000	No comparison	5	SEC filing
Oct 4, 2024	Initial	$1,250,000	No comparison	13	SEC filing
Feb 23, 2024	Initial	$10,193,654	No comparison	46	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-545301

Pursuant to a Securities Purchase Agreement, dated 4/21/2025, up to 10,000 shares of the Company's Series D convertible preferred stock, par value $0.0001 per share shall be purchased for an aggregate purchase price of up to $8M in one or more closings.

Source: Form D, filed May 6, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Brian G. Atwood	Director
Michael Byrnes	Director
Chris Ehrlich	Director, Executive
Andrew Albert Kucharchuk	Executive
Kathleen La Porte	Director
Shami Patel	Director
Kristen Pierce	Executive
Robyn Rapaport	Director
Lindsey Rolfe	Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

201 Haskins Way Suite 230
South San Francisco, CA, 94080
Phone: 650-407-2376